Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/chlorthalidone/losartan potassium - Hanmi Pharmaceutical

Next Previous
Drug Profile

Amlodipine/chlorthalidone/losartan potassium - Hanmi Pharmaceutical

Alternative Names: Amoprel; Amosartan plus L - Hanmi Pharmaceutical; HCP-1803; Low-dose amosartan plus

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypertensives; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Sodium chloride symporter Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 23 Dec 2024 Hanmi Pharmaceutical plans to launch amosartan plus L tablet in 2025
  • 02 Dec 2024 Hanmi Pharmaceutical Company completes a phase III trial for Essential hypertension in South Korea (PO) (NCT06438172)
  • 21 Jun 2024 Efficacy and adverse events data from phase-III HM_APOLLO trial in Essential hypertension released by Hanmi Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top